Loading...

Camurus AB (publ)

CAMRFPNK
Healthcare
Biotechnology
$68.85
$-2.15(-3.03%)

Camurus AB (publ) (CAMRF) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for Camurus AB (publ) (CAMRF), covering cash flow, earnings, and balance sheets.

Revenue Growth
8.78%
8.78%
Operating Income Growth
-11.87%
11.87%
Net Income Growth
-0.71%
0.71%
Operating Cash Flow Growth
-36.07%
36.07%
Operating Margin
37.009%
37.009%
Gross Margin
93.50%
93.50%
Net Profit Margin
31.69%
31.69%
ROE
20.88%
20.88%
ROIC
21.17%
21.17%

Camurus AB (publ) (CAMRF) Income Statement & Financial Overview

Analyze Camurus AB (publ)’s CAMRF earnings with segmented quarterly and yearly financial statement figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$558.34M$553.13M$479.60M$444.87M
Cost of Revenue$39.29M$33.32M$33.51M$35.55M
Gross Profit$519.05M$519.81M$446.08M$409.32M
Gross Profit Ratio$0.93$0.94$0.93$0.92
R&D Expenses$131.45M$167.29M$162.76M$169.80M
SG&A Expenses$157.40M$181.44M$138.52M$154.67M
Operating Expenses$280.17M$353.74M$304.26M$324.47M
Total Costs & Expenses$319.46M$387.06M$337.77M$360.02M
Interest Income$16.41M$20.46M$23.72M$21.78M
Interest Expense$1.33M$284000.00$235000.00$277000.00
Depreciation & Amortization$5.64M$3.51M$3.69M$3.75M
EBITDA$260.94M$190.04M$169.24M$88.59M
EBITDA Ratio$0.47$0.34$0.35$0.20
Operating Income$238.88M$166.07M$141.83M$84.85M
Operating Income Ratio$0.43$0.30$0.30$0.19
Other Income/Expenses (Net)$15.08M$20.18M$23.48M$19.26M
Income Before Tax$253.96M$186.24M$165.31M$104.11M
Income Before Tax Ratio$0.45$0.34$0.34$0.23
Income Tax Expense$56.71M$39.26M$35.96M$29.91M
Net Income$197.25M$146.98M$129.35M$74.20M
Net Income Ratio$0.35$0.27$0.27$0.17
EPS$3.35$2.50$2.21$1.28
Diluted EPS$3.29$2.45$2.16$1.25
Weighted Avg Shares Outstanding$58.88M$58.82M$58.65M$57.78M
Weighted Avg Shares Outstanding (Diluted)$59.92M$59.93M$59.92M$59.53M

The company's financials show resilient growth, with revenue advancing from $444.87M in Q2 2024 to $558.34M in Q1 2025. Gross profit remained healthy with margins at 93% in Q1 2025 compared to 92% in Q2 2024. Operating income hit $238.88M last quarter, sustaining a consistent 43% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $260.94M. Net income rose to $197.25M, while earnings per share reached $3.35. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;